Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents Meeting Abstract
| Authors: | Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; Abdel-Wahab, O. I.; Klimek, V. M. |
| Abstract Title: | Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837600287 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-113840 |
| Notes: | Meeting Abstract: 233 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
